Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
George Zhang
Observed name:
G. Zhang
Institutions:
City Of Hope National Medical Center,
City of Hope,
Beckman Research Institute
Observed institutions:
City Of Hope National Medical Center,
City of Hope,
Beckman Research Institute
ORCID:
0009-0005-6646-7644
Observed ORCID:
0009-0005-6646-7644
OpenAlex ID:
A5127813705
Assessing Geographic Disparities in the Availability of Renal Cell Carcinoma Clinical Trials in the United States
2026
·
George Zhang
, Jadon Fann
, et al.
·
JCO Oncology Practice
·
3
Regional Variation in Bladder Cancer Clinical Trial Availability in the US
2026
·
Koral U. Shah
, Salvador Jaime-Casas
, et al.
·
JAMA Network Open
·
2
Blood Cell Count Ratios Predict Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Treated With First-Line Immune Checkpoint Inhibitors
2026
·
Rahul Winayak
, Kaela Makins
, et al.
·
The Oncologist
PDF
Vulnerability index impacts distribution of prostate cancer clinical trials in the United States
2026
·
Vitor Abreu de Goes
, Benjamin Mercier
, et al.
·
Frontiers in Oncology
PDF
Prediction of immune-related adverse events (irAEs) with hematologic markers in patients receiving first-line immune checkpoint inhibitor (ICI)–based therapy in metastatic renal cell carcinoma (mRCC).
2026
·
Kaela Makins
, Rahul Winayak
, et al.
·
JCO Oncology Practice
PDF
Prevalence and predictors of cachexia in advanced urothelial carcinoma (aUC) patients receiving enfortumab vedotin (EV)–based therapy.
2026
·
George Zhang
, Koral U. Shah
, et al.
·
JCO Oncology Practice
PDF
Collecting duct carcinoma: new biological inroads in this rarest of rare cancers
2026
·
R. Agarwal
, G. Zhang
, et al.
·
ESMO Open
PDF
18 Prediction of Immune-Related Adverse Events (irAEs) with Hematologic Markers in Patients Receiving First-Line Immune Checkpoint Inhibitor (ICI)-Based Therapy in Metastatic Renal Cell Carcinoma (mRCC)
2026
·
Rahul Winayak
, Xiaochen Li
, et al.
·
The Oncologist
PDF
Genomic Characterization of Urothelial Carcinoma and Sarcomatoid Carcinoma of the Upper Urinary Tract
2026
·
Salvador Jaime-Casas
, Nicholas J. Salgia
, et al.
·
Cancers
PDF
Treatment-free survival (TFS) in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV)–based therapy.
2026
·
Salvador Jaime-Casas
, Koral U. Shah
, et al.
·
Journal of Clinical Oncology
Biomarker-defined outcomes in metastatic clear cell renal cell carcinoma (mccRCC) receiving first-line (1L) immune checkpoint inhibitor-based therapy.
2026
·
Koral U. Shah
, Jennifer Rider
, et al.
·
Journal of Clinical Oncology
PDF
Abstract 3911: Use of ALK inhibitors in patients with non-lung malignancies bearing ALK alteration prolongs treatment duration.
2026
·
Vitor Abreu de Goes
, Miguel Zugman
, et al.
·
Cancer Research
Geographic disparities in the availability of renal cell carcinoma (RCC) clinical trials in the United States (US).
2026
·
George Zhang
, Daniela V. Castro
, et al.
·
Journal of Clinical Oncology
PDF
Availability of clinical trials investigating prostate cancer (PC) in the United States (US).
2026
·
Benjamin Mercier
, Vitor Abreu de Goes
, et al.
·
Journal of Clinical Oncology
Regional variations in bladder cancer (BC) clinical trial availability within the United States (US).
2026
·
Koral U. Shah
, George Zhang
, et al.
·
Journal of Clinical Oncology
PDF
Beyond clear cell: Rare histologic and molecular variants of renal cell carcinoma
2026
·
Ali Moradi
, Jadon Fann
, et al.
·
Urologic Oncology Seminars and Original Investigations
Show more works
View as search
Works count:
16
Citation count:
5
H-index:
2
I10-index:
Year
Topic
Type